spacer
home > ebr > winter 2003 > clinical applications of small molecule p38 map kinase inhibitors
PUBLICATIONS
European Biopharmaceutical Review

Clinical Applications of Small Molecule p38 MAP Kinase Inhibitors

Tumour necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-1b) are pro-inflammatory cytokines that play a key role in the communication between cellular components (leukocytes, macrophages, endothelial cells and so on) that drive inflammatory processes underlying a broad range of diseases. Injectable biological therapies specifically targeting the inhibition of TNF-a (infliximab and etanercept) or IL-1 (anakinra) are clinically validated in the treatment of rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and Crohn's disease (CD). TNF inhibitors in particular have become a gold standard of disease-modifying treatment in patients with severe RA.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Leslie Williams, Program Executive for Vertex's p38 MAP Kinase Development Team

Dr Leslie Williams is Program Executive for Vertex's p38 MAP kinase development team and is also Head of Drug Safety and Medical Writing at Vertex. Leslie joined Vertex in 2000 after seven years of clinical experience in medical information and Phase III and IV post-marketing safety surveillance at two major pharmaceutical companies. Leslie holds a Doctorate of Veterinary Medicine and is a Diplomat of the American College of Veterinary Anesthesiology. Prior to joining the pharmaceutical industry, Leslie served as a Faculty Member and Section Head of Anesthesia at Tufts University School of Veterinary Medicine.

spacer
Dr Leslie Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement